Corrigendum to “GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study” eClinicalMedicine 2024;73:102661

After publication, we identified that Wharton et al. (2023) had been erroneously included among the randomised controlled trials (RCTs) informing the semaglutide evidence base (doi.org/10.1002/oby.23673). We sincerely regret this error and have corrected the analyses accordingly. The publication was a secondary analysis of the STEP 5 trial, whose primary report by Garvey et al. (2022) was included in the analysis. This inclusion therefore unintentionally double-counted the same trial population.